Baidu
map

第五届中法肿瘤论坛:MedSci专访大会主席陈昶教授及Amaury Martin先生

2015-11-23 MedSci MedSci原创

中法专家齐聚一堂  共绘肺癌诊疗蓝图——中法肿瘤论坛大会主席专访实录【编者按】11月13日,由同济大学附属上海市肺科医院、同济大学和《中国癌症杂志》共同主办的第五届中法肿瘤论坛在上海同济大学中法研究中心隆重召开。在会议现场,MedSci小编有幸对同济大学附属上海市肺科医院副院长、我国著名肺外科专家陈昶教授以及CLARA总秘书长Amaury Martin先生进行了专访。谈到中法肿瘤论坛的背

中法专家齐聚一堂  共绘肺癌诊疗蓝图
——中法肿瘤论坛大会主席专访实录

【编者按】11月13日,由同济大学附属上海市肺科医院、同济大学和《中国癌症杂志》共同主办的第五届中法肿瘤论坛在上海同济大学中法研究中心隆重召开。在会议现场,MedSci小编有幸对同济大学附属上海市肺科医院副院长、我国著名肺外科专家陈昶教授以及CLARA总秘书长Amaury Martin先生进行了专访。



谈到中法肿瘤论坛的背景,陈昶教授如数家珍。本届中法肿瘤论坛的顺利召开离不开上海市政府层面的支持以及中法双方科技合作的大背景。上海市与法国罗阿大区(罗讷-阿尔卑斯[Rhone-Alpes]大区)本就是友好城市,加之上海市科委有推动中国·上海与其他城市科技协作的专业项目,其中重点之一就在医疗卫生领域。去年习主席访法以及上海市卫计委组织中国医生赴法参加上届论坛,都进一步推动了上海市与法国罗阿大区的科技协作。陈教授透露,论坛设在同济大学中法研究中心举行具有特别的考量:本届会议得到了同济大学的大力支持;此外,当年的法国时任总统曾见证该中心的落成。

陈昶教授评价,本届中法肿瘤论坛是一个东西方专家之间、内外科多学科之间交流的高水平学术平台,能够碰撞出更多思想火花,有利于学术研究的产生与合作。高水平、高质量的国际交流学术平台会吸引更多其他学科的专业人员,如转化医学研究者、医药企业研发人员等,临床医生与其合作可以促进研究到临床实践的迅速转化。这些对医学研究和临床诊疗水平的发展具有重要意义。

烟草与肺癌是本届论坛的重要学术议题。陈昶教授指出,目前中国烟草消费现状严峻,控烟工作刻不容缓。同时,肺癌的发病率与致死率依然排在癌症第一位,肺癌相关研究将是医疗机构科学研究的一个重要课题,特别是在即将到来的十三五期间。陈昶教授表示,上海市肺科医院计划在十三五期间投入更多的精力在肺癌研究领域。

目前,关于早期肺癌的医学研究方向主要集中在三个方面:第一,肺部小结节的诊断标准与诊断方法;第二,公众对癌症的认知以及高危、易感人群进行癌症筛查的自觉性;第三,目前的肺癌的生物学性状与以往的肺癌生物学性状发生了哪些改变。陈昶教授领衔的团队研究重点集中在:确定肺癌易感人群、肺癌手术临床规范标准、肺癌患者术后预后预判方案以及外科手术技术与设备方面的研究。



本届中法肿瘤论坛的法方代表、CLARA总秘书长Amaury Martin在接受采访时向MedSci小编介绍,参加本届中法肿瘤论坛的法方专家团,大多来自世界知名癌症研究所——里昂奥维涅-罗纳-阿尔卑斯癌症研究中心(CLARA)和Albert Bonniot肿瘤研究所,包括Albert Bonniot肿瘤研究所所长Pierre Hainaut在内的法方团队在本届中法肿瘤论坛上分享了肺癌遗传学分子机理、癌细胞代谢、肺癌药物疗效等领域的前沿信息。

谈到对本届会议的印象,Martin先生多次用到了“wonderful”。他认为,本届论坛除了吸引众多的肺科医生外,还有不少年轻的医学生也踊跃参会,这更有益于会议信息的传播与思想碰撞。其次,本届会议参会人员综合素质较高,Martin先生衷心希望中法双方的参会人员都能从本次学术活动中有所收获,从而促进东西方医学信息交流、思想和技术交流以及推动医学发展。第三,本届论坛各项会务组织与安排工作效率极高,这与上海市肺科医院的大力支持是分不开的。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=206639, encodeId=ee00206639a7, content=肺部小结节的诊治是重点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEYA6ZJS2RZEJp0LgvdXH072EszfvD8xib0UGViaFO626UZIkB4ibvY1NicVJDFUSYoQjZvL6gnjziaYl/0, createdBy=48511932758, createdName=1e0d2fb7m34(暂无匿称), createdTime=Mon Jun 05 06:27:33 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93585, encodeId=9f6993585e4, content=值得大家去学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93584, encodeId=8d059358440, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703202, encodeId=f2a11e032022b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 05 17:39:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356035, encodeId=002413560352b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606724, encodeId=01151606e2493, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=)]
    2017-06-05 1e0d2fb7m34(暂无匿称)

    肺部小结节的诊治是重点

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=206639, encodeId=ee00206639a7, content=肺部小结节的诊治是重点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEYA6ZJS2RZEJp0LgvdXH072EszfvD8xib0UGViaFO626UZIkB4ibvY1NicVJDFUSYoQjZvL6gnjziaYl/0, createdBy=48511932758, createdName=1e0d2fb7m34(暂无匿称), createdTime=Mon Jun 05 06:27:33 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93585, encodeId=9f6993585e4, content=值得大家去学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93584, encodeId=8d059358440, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703202, encodeId=f2a11e032022b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 05 17:39:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356035, encodeId=002413560352b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606724, encodeId=01151606e2493, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=)]
    2016-07-19 doctorJiangchao

    值得大家去学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=206639, encodeId=ee00206639a7, content=肺部小结节的诊治是重点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEYA6ZJS2RZEJp0LgvdXH072EszfvD8xib0UGViaFO626UZIkB4ibvY1NicVJDFUSYoQjZvL6gnjziaYl/0, createdBy=48511932758, createdName=1e0d2fb7m34(暂无匿称), createdTime=Mon Jun 05 06:27:33 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93585, encodeId=9f6993585e4, content=值得大家去学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93584, encodeId=8d059358440, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703202, encodeId=f2a11e032022b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 05 17:39:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356035, encodeId=002413560352b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606724, encodeId=01151606e2493, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=)]
    2016-07-19 doctorJiangchao

    支持

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=206639, encodeId=ee00206639a7, content=肺部小结节的诊治是重点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEYA6ZJS2RZEJp0LgvdXH072EszfvD8xib0UGViaFO626UZIkB4ibvY1NicVJDFUSYoQjZvL6gnjziaYl/0, createdBy=48511932758, createdName=1e0d2fb7m34(暂无匿称), createdTime=Mon Jun 05 06:27:33 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93585, encodeId=9f6993585e4, content=值得大家去学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93584, encodeId=8d059358440, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703202, encodeId=f2a11e032022b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 05 17:39:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356035, encodeId=002413560352b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606724, encodeId=01151606e2493, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=206639, encodeId=ee00206639a7, content=肺部小结节的诊治是重点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEYA6ZJS2RZEJp0LgvdXH072EszfvD8xib0UGViaFO626UZIkB4ibvY1NicVJDFUSYoQjZvL6gnjziaYl/0, createdBy=48511932758, createdName=1e0d2fb7m34(暂无匿称), createdTime=Mon Jun 05 06:27:33 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93585, encodeId=9f6993585e4, content=值得大家去学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93584, encodeId=8d059358440, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703202, encodeId=f2a11e032022b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 05 17:39:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356035, encodeId=002413560352b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606724, encodeId=01151606e2493, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=)]
    2015-11-25 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=206639, encodeId=ee00206639a7, content=肺部小结节的诊治是重点, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuEYA6ZJS2RZEJp0LgvdXH072EszfvD8xib0UGViaFO626UZIkB4ibvY1NicVJDFUSYoQjZvL6gnjziaYl/0, createdBy=48511932758, createdName=1e0d2fb7m34(暂无匿称), createdTime=Mon Jun 05 06:27:33 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93585, encodeId=9f6993585e4, content=值得大家去学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:51:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=93584, encodeId=8d059358440, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Tue Jul 19 13:50:00 CST 2016, time=2016-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703202, encodeId=f2a11e032022b, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Thu May 05 17:39:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356035, encodeId=002413560352b, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606724, encodeId=01151606e2493, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 25 04:39:00 CST 2015, time=2015-11-25, status=1, ipAttribution=)]

相关资讯

CGLCF:MedSci专访大会主席周彩存教授——共襄盛会话诊疗发展 集聚智慧谋患者福祉

11月13日,上海市肺科医院、德国海德堡大学与中国抗癌协会肺癌专业委员会共同主办的第七届中德肺癌论坛暨第十七届肺癌生物靶向与个体化治疗新进展学习班在上海召开。梅斯医学(MedSci)小编有幸在会议现场采访本届大会主席周彩存教授。 周教授在采访中介绍,本届论坛亮点纷呈,吸引了来自全国众多肺癌诊疗临床工作者,实际参会人数超过会议设计之初的2倍之多。本届会议在阵容方面,除了国内肺癌诊疗领域顶级专家,如

第五届中法肿瘤论坛成功举办

11月14至16日,由我院主办的第五届中法肿瘤论坛(5th Chinese-French Symposium on Cancer Research)在同济大学中法中心成功举办。副院长陈昶教授担任论坛主席。开幕式上,同济大学副校长吕培明回顾了上海市与法国罗讷-阿尔卑斯大区在过去数年间多个领域的交流与合作,尤其对肿瘤研究领域的成果表示认可。肺科医院党委书记张雷教授致辞欢迎来自法国CLARA及Alber

关注肿瘤标志物检测,改善肺癌管理——ProGRP检测助力小细胞肺癌的临床诊疗

今年11月是第十五个“全球肺癌关注月”,这是世界肺癌联盟在2001年11月发起的一项全球性倡议,目的是呼吁世界各国重视肺癌的预防,提高人们对肺癌的防癌、抗癌意识,普及肺癌的规范化诊疗知识。作为一种常见的高致死率恶性肿瘤,全球每年约有160万新发肺癌病例,每年因肺癌死亡的人数超过其他高发癌症死亡人数之和。在中国,情况同样不容乐观,每4例恶性肿瘤死亡者中就有1例是肺癌患者。肺癌已成为我国恶性肿瘤发

抗癌药物的伴随诊断,下一代测序(NGS)扮演何种角色?

【导读】根据分析师的预测,全球体外诊断市场将从2014年的31.4亿美元增加到2019年的87.3亿美元。在药物临床试验阶段,伴随诊断具有很好的用药指导作用,一方面可以提高治疗的响应准确度;另一方面通过对患者的用药分层预测和识别用药人群,节省患者的用药开支。 伴随诊断(CDx),是指采用体外诊断设备(试剂)或影像学工具,为治疗性的产品提供安全、有效的指示作用;显而易见伴随诊断已经成为肿瘤学家

全球肺癌关注月:专家呼吁加快肺癌突破性新药审批进程

11月是全球肺癌关注月,国际肺癌研究协会发布的《2015年肺癌情况简报》显示:肺癌是全球癌症死亡的主要原因,每年超过160万人死于肺癌。但肺癌不一定是致命的,新的突破性治疗方法显著提高了肺癌患者存活率。对于已确诊的肺癌病人,根据其肿瘤的具体特征而选择适当药物进行个体化治疗十分重要。今天,在第七届中德肺癌论坛(CGLCF)上,论坛组织者同济大学医学院肿瘤研究所所长,肿瘤学系主任,上海市肺科医院肿

上海胸科医院进行PD-1单抗nivolumab在肺癌中三期临床试验

“最近,一个病人在香港使用PD-1单抗以后,病情有了一些变化。原来不能起身现在能下地行走了。”这是上海胸科医院肺部肿瘤临床医学中心主任陆舜对他其中一个患者病情的简单介绍。当这样的情形发生在一个晚期肺癌病人身上时,多少令人有些惊叹。因为如果患者继续接受传统的放化疗治疗,到这个阶段基本上病情好转的希望已经渺茫。陆舜看了很多国外临床试验的资料后,他觉得这个病人病情的好转肯定不是一个偶然。“肿瘤免疫疗法已

Baidu
map
Baidu
map
Baidu
map